We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+19.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
+$244M
Cap. Flow
+$74.7M
Cap. Flow %
4.68%
Top 10 Hldgs %
27.52%
Holding
150
New
14
Increased
55
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$36M
2
AMRN
Amarin Corp
AMRN
+$13.9M
3
TSRO
TESARO, Inc.
TSRO
+$13.7M
4
DHR icon
Danaher
DHR
+$12.8M
5
PTHN
Patheon N.V.
PTHN
+$11M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
2
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.8M
4
MD icon
Pediatrix Medical
MD
+$9.92M
5
XNPT
XENOPORT, INC.
XNPT
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
2 Financials 3.67%
3 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATYR
126
aTyr Pharma
ATYR
$50.1M
$1.38M 0.09%
30,964
– –
BLUE
127
DELISTED
bluebird bio
BLUE
$1.36M 0.09%
1,544
– –
CERN
128
DELISTED
Cerner Corp
CERN
$1.24M 0.08%
20,000
– –
INSY
129
DELISTED
Insys Therapeutics, Inc.
INSY
$1.18M 0.07%
100,000
-265,500
-73% -$4.04M
MDGL icon
130
Madrigal Pharmaceuticals
MDGL
$11.8B
$799K 0.05%
+63,000
New +$610K
DARE icon
131
Dare Bioscience
DARE
$21M
$654K 0.04%
5,208
– –
OREX
132
DELISTED
Orexigen Therapeutics, Inc.
OREX
$549K 0.03%
165,300
– –
INFI
133
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$421K 0.03%
270,000
– –
ARIA
134
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$342K 0.02%
+25,000
New +$251K
SYBX
135
DELISTED
Synlogic
SYBX
– –
-1,429
Closed -$639K
TEVA icon
136
Teva Pharmaceuticals
TEVA
$41.2B
– –
-395,000
Closed -$19.8M
TMO icon
137
Thermo Fisher Scientific
TMO
$220B
– –
-100,200
Closed -$14.8M
ICPT
138
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-10,000
Closed -$1.43M
CYTO
139
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-11
Closed -$3.56M
INOV
140
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
– –
-104,302
Closed -$1.88M
ARA
141
DELISTED
American Renal Associates Holdings, Inc
ARA
– –
-250,000
Closed -$7.24M
PTLA
142
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-175,000
Closed -$4.13M
TSRO
143
CALL
DELISTED
TESARO, Inc.
TSRO
– –
-40,000
Closed -$3.36M
RLYP
144
DELISTED
RELYPSA INC COM
RLYP
– –
-75,000
Closed -$1.39M
HTWR
145
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-311,000
Closed -$18M
XNPT
146
DELISTED
XENOPORT, INC.
XNPT
– –
-1,195,000
Closed -$8.41M
SPHS
147
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-490,000
Closed -$1.05M
2 3 4 5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rock Springs Capital Management held 150 positions worth $1.6B, up 18% from $1.35B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $74.7M of net new capital in Q3 2016, opening 14 new positions and adding to 55 existing holdings. Its largest new stake was Merck: 615,700 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Pediatrix Medical, an estimated $9.92M trimmed.

  • Rock Springs Capital Management's largest Q3 2016 buy was Merck: 615,700 shares worth $36.7M.
  • Rock Springs Capital Management added most to TESARO, Inc. in Q3 2016, an estimated $13.7M increase.
  • Rock Springs Capital Management's biggest Q3 2016 reduction was Pediatrix Medical, cutting an estimated $9.92M.
  • Rock Springs Capital Management fully exited Teva Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.6B portfolio in Q3 2016.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q3 2016.
  • Rock Springs Capital Management's portfolio value rose 18% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.